vs
Side-by-side financial comparison of Coya Therapeutics, Inc. (COYA) and CITIUS ONCOLOGY, INC. (CTOR). Click either name above to swap in a different company.
Coya Therapeutics, Inc. is the larger business by last-quarter revenue ($4.0M vs $3.9M, roughly 1.0× CITIUS ONCOLOGY, INC.).
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative regulatory T cell (Treg)-based therapies to address unmet medical needs for patients with neurodegenerative, autoimmune, and inflammatory diseases. Its core pipeline includes lead candidates targeting conditions like amyotrophic lateral sclerosis, with primary planned commercial markets across North America and the European Union.
Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.
COYA vs CTOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.0M | $3.9M |
| Net Profit | — | $-5.5M |
| Gross Margin | — | 80.0% |
| Operating Margin | — | -133.2% |
| Net Margin | — | -140.3% |
| Revenue YoY | 202768.8% | — |
| Net Profit YoY | -95.8% | 16.9% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.0M | $3.9M | ||
| Q3 25 | $3.6M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $3.4M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $-2.1M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | $-2.9M | — |
| Q4 25 | — | 80.0% | ||
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -133.2% | ||
| Q3 25 | -68.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -94.5% | — |
| Q4 25 | — | -140.3% | ||
| Q3 25 | -59.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -84.4% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.13 | — | ||
| Q3 24 | $-0.26 | — | ||
| Q2 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $46.8M | $7.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $43.0M | $58.4M |
| Total Assets | $50.0M | $110.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.8M | $7.3M | ||
| Q3 25 | $28.1M | — | ||
| Q3 24 | $31.1M | — | ||
| Q2 24 | $36.6M | — |
| Q4 25 | $43.0M | $58.4M | ||
| Q3 25 | $27.3M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $35.3M | — |
| Q4 25 | $50.0M | $110.0M | ||
| Q3 25 | $32.0M | — | ||
| Q3 24 | $35.6M | — | ||
| Q2 24 | $39.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.7M | $-7.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.7M | $-7.4M | ||
| Q3 25 | $-1.1M | — | ||
| Q3 24 | $-5.5M | — | ||
| Q2 24 | $-4.6M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
